AstraZeneca CICC Medical Industry Fund
阿斯利康中金医疗产业基金
AstraZeneca CICC Medical Industry Fund is a China-focused healthcare investment fund that has backed several biotech and pharmaceutical companies in recent years. It co-led AXBIO's nearly $100 million Series B round in 2022 alongside Yunfeng Capital , and has been a repeat investor in Kailan Pharma (Cholesgen), participating in the company's Series A in 2023 and following on in its A+ round in early 2025 . The fund also appears in a strategic partnership context: in March 2025, AstraZeneca itself partnered with Syneron Bio to develop macrocyclic peptide drugs for chronic diseases, with up to $3.4 billion in milestone payments — though this was a direct corporate deal rather than fund investment. The fund's activity clusters in biotech and innovative drug development, with particular interest in sequencing technology and metabolic disease therapeutics.
AI-generated — may contain errors, please verify.
Coverage
Rongbao | Generative AI and medical device companies close new funding rounds, setting domestic records in their respective sectors
The Power of Aspiration.
Kailan Pharma Closes Oversubscribed A+ Round of Over 100 Million RMB to Advance Cholesterol Metabolism Drug R&D
Striving to provide alternative treatment options for patients with metabolic diseases.
Kailan Pharma Closes Oversubscribed Series A Financing of Over 100 Million RMB to Advance Innovative Drug Development in Cholesterol Metabolism
Gaorong Ventures led the round.
July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
5Y News | Axbio Closes Nearly $100M Series B Funding Round
Make faster, more accessible, ultra-low-cost sequencing products available to the life sciences and healthcare industries.
